Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis
Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis
复制标题
全身性皮质类固醇治疗伴有 Vogt-Koyanagi-Harada 病或结节病的非感染性葡萄膜炎复发的多中心、回顾性、观察性研究
DOI：
10.1007/s10384-021-00897-7
复制
发表时间：
2022
影响因子：
2.4
通讯作者：
Kaburaki Toshikatsu
中科院分区：
文献类型：
--
作者：
Namba Kenichi;Takase Hiroshi;Usui Yoshihiko;Nitta Fumihiko;Maruyama Kazuichi;Kusuhara Sentaro;Takeuchi Masaki;Azumi Atsushi;Yanai Ryoji;Kaneko Yutaka;Hasegawa Eiichi;Nakai Kei;Tsuruga Hidekazu;Morita Kazuo;Kaburaki Toshikatsu
目的：与Vogt-Koyanagi-Harada （VKH）病或结节病相关的非感染性葡萄膜炎通常使用全身皮质类固醇（SCS）治疗。我们评估了在日本临床实践中使用SCS治疗非感染性葡萄膜炎复发的情况。研究设计：多中心，回顾性图表审查（UMIN临床试验注册；UMIN000032390）。方法2011年8月- 2018年12月，157例（15岁≤75岁；VKH病103例，结节病54例）患者接受SCS治疗合并VKH病或结节病的非感染性中间、后或全葡萄膜炎复发。分析靶向复发治疗后12个月的SCS剂量和持续时间、伴随药物、随后的复发和类固醇相关药物不良反应（adr）。分析背景因素与SCS总剂量之间的关系（logistic回归）。结果目标复发治疗后12个月内SCS的平均（±SD）总剂量为3874±2775 mg，使用免疫抑制剂的患者高于未使用免疫抑制剂的患者（4575 mg vs 3496 mg）。使用免疫抑制剂是唯一与高SCS总剂量显著相关的因素（p = 0.0196）。SCS治疗复发的平均持续时间为318.7±89.3天。12个月后，只有29.3%的患者不再使用类固醇；在未使用免疫抑制剂的患者中，这一比例更高（36.3% vs 16.4%）。39.5%的患者出现复发，13.4%的患者出现类固醇相关不良反应（主要是青光眼或糖尿病）。结论在日本的临床实践中，许多复发性葡萄膜炎合并VKH病或结节病的患者在复发≥300天时接受了SCS治疗，这表明对于难以抑制炎症的患者，减少糖皮质激素是具有挑战性的。
PurposeNon-infectious uveitis associated with Vogt-Koyanagi-Harada (VKH) disease or sarcoidosis is commonly treated with systemic corticosteroids (SCS). We assessed the use of SCS for non-infectious uveitis relapses in Japanese clinical practice.Study designMulticenter, retrospective chart review (UMIN Clinical Trial Registry; UMIN000032390).MethodsOne hundred fifty-seven patients (15– ≤ 75 years; 103 VKH disease, 54 sarcoidosis) given SCS to treat a relapse of non-infectious intermediate, posterior, or panuveitis accompanying VKH disease or sarcoidosis were studied (August 2011–December 2018). SCS dose and duration, concomitant medications, subsequent relapses, and steroid-related adverse drug reactions (ADRs) were analyzed for 12 months after target relapse treatment. Relationships between background factors and total SCS dose were analyzed (logistic regression).ResultsMean (± SD) total SCS dose over 12 months after target relapse treatment was 3874 ± 2775 mg, and was higher in patients with immunosuppressants than in those without (4575 mg vs 3496 mg). Immunosuppressant use was the only factor significantly associated with higher total SCS dose (p = 0.0196). Mean duration of SCS treatment for relapse was 318.7 ± 89.3 days. Only 29.3% of patients were steroid-free after 12 months; the percentage was higher in patients without immunosuppressants (36.3% vs 16.4%). Subsequent relapse was experienced by 39.5% of patients, and 13.4% had a steroid-related ADR (mostly glaucoma or diabetes).ConclusionIn Japanese clinical practice, many patients with recurrent uveitis accompanying VKH disease or sarcoidosis received SCS for relapse for ≥ 300 days, suggesting that reducing corticosteroids is challenging in patients with difficulty suppressing inflammation.
登录
查看更多内容
影响因子：
5.5
作者：
Ruiz-Arruza, Ioana;Ugarte, Amaia;Ruiz-Irastorza, Guillermo
通讯作者：
Ruiz-Irastorza, Guillermo
影响因子：
13.7
作者：
Kaçmaz RO;Kempen JH;Newcomb C;Daniel E;Gangaputra S;Nussenblatt RB;Rosenbaum JT;Suhler EB;Thorne JE;Jabs DA;Levy-Clarke GA;Foster CS
通讯作者：
Foster CS
日本用于治疗眼部炎症疾病的生物制剂。
DOI：
--
发表时间：
2019
期刊：
影响因子：
--
作者：
Okinaga K;Tanaka R;Komae K;Izawa H;Nakahara H;Shirahama S;Soga H;Ono H;Yoshida A;Kawashima H;Kaburaki T.;橋田徳康;Kaburaki T.
通讯作者：
Kaburaki T.
[结节病诊断指南和标准 - 2006 年]。
DOI：
--
发表时间：
2008
期刊：
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society
影响因子：
--
作者：
K. Sugisaki
通讯作者：
K. Sugisaki
原发性肾病综合征成年患者的隐球菌性脑膜炎。
影响因子：
1.1
作者：
B. Su;Qiankun Zhang;Jin Lv
通讯作者：
Jin Lv